Premium
PHASE 2 STUDY OF PARSACLISIB (INCB050465) FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (CITADEL‐202)
Author(s) -
Belada D.,
Fay K.,
Casasnovas R.,
Gressin R.,
Lee H.,
Mehta A.,
Munoz J.,
Verhoef G.,
Corrado C.,
DeMarini D.,
Zhao W.,
Chen X.,
Coleman M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.138_2630
Subject(s) - medicine , refractory (planetary science) , diffuse large b cell lymphoma , gastroenterology , bruton's tyrosine kinase , lymphoma , interim analysis , oncology , nuclear medicine , clinical trial , tyrosine kinase , physics , receptor , astrobiology